KOL Lunch CAR-T NKG2D Cell Therapy for the Treatment of Blood Cancers, hosted by Celyad

The meeting will feature a presentation by Key Opinion Leader Marco Davila, MD, PhD (Moffitt Cancer Center), who will discuss the evolving treatment landscape of CAR-T therapies in development, as well as the unmet medical need for treating patients with blood cancers, including Acute Myeloid Leukemia (AML).